J&J Procrit Once-Weekly Labeling Resubmitted To FDA
Executive Summary
Johnson & Johnson is hoping for approval of a supplemental BLA for once-weekly use of Procrit in chemotherapy patients by mid-2004
You may also be interested in...
J&J Procrit Gains Once-Weekly Dosing In Chemotherapy Patients
Johnson & Johnson's Procrit (epoetin alfa) approval for once-weekly dosing in chemotherapy patients should relieve one of the marketing challenges it has had in facing Amgen's Aranesp (darbepoetin)
J&J Procrit Gains Once-Weekly Dosing In Chemotherapy Patients
Johnson & Johnson's Procrit (epoetin alfa) approval for once-weekly dosing in chemotherapy patients should relieve one of the marketing challenges it has had in facing Amgen's Aranesp (darbepoetin)
J&J Draws Line On Procrit Price; Will Not Meet Amgen Aranesp 40% Discount
Johnson & Johnson will not be matching Amgen's latest discounts in the EPO market, J&J CFO Robert Darretta indicated during an April 13 investor call